(Q38246377)

1 September 2017

title

Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). (English)

1 reference

1 September 2017

0 references

1 reference

Stephen J Seligman

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

3 September 2014

1 reference

1 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

1 September 2017

volume

32

1 reference

1 September 2017

issue

44

1 reference

1 September 2017

page(s)

5769-5775

1 reference

Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Dengue and yellow fever--challenges for the development and use of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Review of the risks and benefits of yellow fever vaccination including some new analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

History of thymoma and yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Yellow fever virus vaccine-associated deaths in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Safety profile of the yellow fever vaccine Stamaril®: a 17-year review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Viscerotropic disease following yellow fever vaccination in Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Yellow Fever Vaccine Post-marketing Surveillance in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Autoantibodies against cytokines: back to human genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Direct evidence for thymic function in adult humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Yellow fever vaccine-associated adverse events following extensive immunization in Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Human genetics of infectious diseases: between proof of principle and paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

The genetic theory of infectious diseases: a brief history and selected illustrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Global distribution of the CCR5 gene 32-basepair deletion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

Fulminant hepatitis in dengue haemorrhagic fever.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.051

10.1016/J.VACCINE.2014.08.051

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference